This Roundtable supports partnerships between payer, provider, life sciences and technology companies that support a new level of IT deployment in health care, including digital health, interoperability, new forms of data, integrated clinical trials and AI/ML, that can drive better and more equitable patient outcomes through modernization and implementation of consumer engagement, population health and care delivery, during and after COVID. Special attention will be paid to cybersecurity and privacy. The goal of this Roundtable is to set a new foundation for care that is longitudinal, fully integrated and patient centered while considering the impact of changes on physician burnout.
Each Forum Roundtable strikes a balance between near-term COVID-related challenges and long-term impact on major issues in the post-pandemic world through professional facilitation and deep subject matter expertise. The groups will develop and widely disseminate recommendations that will make an impact on provider, payer and life sciences CEOs, policymakers and thought leaders collaborating for industry-wide change.
Amy Abernethy, MD, PhD, President, Clinical Research Business, Verily; former Principal Deputy Commissioner, FDA
Aneesh Chopra, President, CareJourney
Steve Klasko, MD, President & CEO, Thomas Jefferson University and Jefferson Health
Peter Neupert, Lead Director, Adaptive Biotechnologies Corp.; Former VP, Microsoft Health Solutions
Steve Udvarhelyi, MD, President & CEO, Blue Cross and Blue Shield of Louisiana
Arien Malec, SVP R&D Clinical and Administrative Networks, Change Healthcare
Brian Ancell, President & COO, League
Amy Abernethy, MD, PhD, Verily; formerly FDA
Nancy Howell Agee, Carilion Clinic
Lisa Alderson, Genome Medical
Gina Bartasi, Kindbody
Michael Blum, UCSF Health
David Braza, Premera Blue Cross
Niall Brennan, Health Care Cost Institute
Aneesh Chopra, CareJourney
Toby Cosgrove, MD, Cleveland Clinic
Molly Coye, MD, AVIA
Neil de Crescenzo, Change Healthcare
Ellen Duffield, Gateway Health Plan
Esther Dyson, Wellville
Shamiram Feinglass, MD, Danaher Corp
Josh Goode, SCAN Health Plan
Gary Guthart, PhD, Intuitive Surgical, Inc.
Eric Hargan, former Deputy Secretary of the US Department of Health and Human Services
James Hereford, Fairview Health Services
David Horrocks, Chesapeake Regional Information System for Patients
Cynthia Hundorfean, Allegheny Health Network
Frank Ingari, Tandigm Health
Charles Jaffe, HL7
Steve Klasko, MD, Thomas Jefferson University Hospital
Thomas Maddox, MD, BJC HealthCare/Washington University School of Medicine
Carolyn Magill, Aetion
Arien Malec, Change Healthcare
Aaron Martin, Providence St. Joseph Health
Rob Metcalf, Concert Genetics
Randall Moore, MD, Franciscan Health
Peter Neupert, Adaptive Biotechnologies
Peter Orszag, Lazard
Jon Perlin, HCA Healthcare
David Ricks, Eli Lilly and Company
Rajeev Ronanki, Anthem, Inc.
Cris Ross, Mayo Clinic
Michael Serbinis, League, Inc.
Mario Schlosser, Oscar Health
Eric Schneider, MD, The Commonwealth Fund
Tom Stanis, Story Health
Warner Thomas, Ochsner Health System
Steve Udvarhelyi, MD, Blue Cross and Blue Shield of Louisiana
Work Groups are chartered by Roundtables to go deep on a key issue over a three-year period, and to make recommendations to Roundtable Fellows for pronouncements or actions that should be taken by the Roundtable, the Forum or by all CEOs. Work Groups are focused on:
There has been huge growth and large expectations for the use of patient data in health care, particularly as an adjuvant to clinical decision-making. From image interpretation to diagnosis, payer, provider and life science companies are forming partnerships with technology and data analytics companies to develop new tools and capabilities. However, payer, provider and life science companies face potential public backlash and regulatory scrutiny over data privacy concerns when engaging outside partners to analyze PHI and non-PHI data, and use of patient data in new ways may create health disparities and pose other ethical challenges for payer, provider and life science companies. While the FDA regulates AI tools that are used in diagnosis or treatment, the lack of guidelines for how AI should be developed, how patient data should be used, how AI is applied to various populations (e.g., across races or age groups) and how AI intellectual property is handled puts payer, provider and life science companies at risk. The goal of this Work Group is to articulate standards for responsible innovation to shape the partnerships between payer, provider and life science companies and developers of AI and other analytics and to guide the product development process of data tools for the clinical setting.
There are hundreds of thousands of health care apps that influence the health of people who are otherwise patients of health systems and members of health plans. These organizations have no way of knowing which apps people are using or whether they are appropriate for their health status. Likewise, many health systems and health plans have digital strategies that, while thoughtful, result in a piecemeal, arbitrary and fragmented set of apps that patients use. The goal of this Work Group is to identify the best practices for rationalizing patient/member app and digital health experience and to widely disseminate these practices.